{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-146576","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.335480+00:00","generated_at":"2026-06-14T22:30:53.218402+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IN8bio preclinical data shows DeltEx gamma-delta T cells kill ovarian cancer cells, including resistant lines","bullets":["Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.","Temozolomide (TMZ) combined with PARP inhibitors synergistically increased NKG2D-L expression, enhancing tumor cell visibility to gamma-delta T cells.","CEO William Ho highlighted synergy of gamma-delta T cells with chemotherapy for solid tumors beyond the brain.","CSO Lawrence Lamb noted potential for INB-400 in ovarian cancer and other solid tumors; further evaluation planned.","Preclinical proof-of-concept supports DeltEx Drug Resistance Immunotherapy (DeltEx DRI) platform in challenging indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-146576","json":"https://secwatch.observer/filing/0001193125-23-146576.json","markdown":"https://secwatch.observer/filing/0001193125-23-146576.md","text":"https://secwatch.observer/filing/0001193125-23-146576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/0001193125-23-146576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/d477840d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T22:30:53.218402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}